Can chronic inflammation and insulin resistance lower hepatic SHBG even when thyroid labs are normal?

Research consistently demonstrates that hepatic sex hormone-binding globulin (SHBG) production is sensitive to metabolic and inflammatory signaling, often independent of thyroid status.

Clinical evidence and metabolic mediation

Clinical data across various cohorts indicate that SHBG functions as a sensitive marker for hepatic metabolic health.

• Inflammatory markers: In euthyroid populations (those with normal thyroid labs), higher levels of C-reactive protein (CRP) and Interleukin-6 (IL-6) are significantly associated with lower SHBG levels. For instance, in a large cross-sectional study of 2,242 adults, each 1-SD increase in CRP was associated with a 5.6 nmol/L decrease in SHBG, independent of BMI and insulin resistance.
• Insulin resistance: Insulin resistance (HOMA-IR) and hyperinsulinemia are potent suppressors of SHBG. Human liver cohort studies show that hepatic fat content and insulin resistance correlate with a 40–60% reduction in SHBG mRNA levels compared to healthy controls.
• Euthyroid independence: While thyroid hormone (T3/T4) stimulates SHBG, the suppressive effects of chronic inflammation and insulin resistance are powerful enough to lower SHBG even when thyroid-stimulating hormone (TSH) and free thyroid hormones are within the reference range.

Mechanistic explanations

The suppression of SHBG is primarily mediated through the downregulation of Hepatocyte Nuclear Factor-4 alpha (HNF-4α), the master transcriptional regulator of the SHBG gene in the liver.

• Cytokine pathways: Pro-inflammatory cytokines like TNF-α and IL-1β activate the NF-κB and JNK/MAPK signaling pathways in hepatocytes. This activation reduces the expression and transcriptional activity of HNF-4α, leading to a direct decrease in SHBG gene transcription.
• Insulin signaling: High insulin levels further suppress HNF-4α. This creates a convergent pathway where metabolic stress (insulin) and immune stress (cytokines) both act on the same genetic "switch" to reduce SHBG output.
• Potential bidirectional feedback: Emerging research suggests that SHBG itself may have anti-inflammatory properties. In experimental models, SHBG has been shown to suppress NF-κB activation and reduce the production of TNF-α and IL-6 in macrophages and adipocytes, suggesting that low SHBG may further exacerbate a pro-inflammatory state.

Bottom line

Chronic low-grade inflammation and insulin resistance are primary drivers of low SHBG. Because these factors directly suppress the hepatic transcription of SHBG via the HNF-4α pathway, low SHBG levels often serve as a metabolic "red flag" for systemic inflammation even when thyroid function appears normal.